Latest From MDxHealth SA
Market Intel: Precision Diagnostics And Focal Treatments Offer Personalized Approach To Prostate Cancer
The combined market for prostate cancer diagnostics and minimally invasive treatments is set to increase from $900m to $1.46bn in the next five years. But conservative treatment, or watchful waiting, is popular, limiting growth of newer, focal treatments.
MDx Health has signed an exclusive distribution deal to make its liquid biopsy prostate cancer test available in Canada.
Derived from Strategic Transactions, Informa’s premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech column pulls up notable technology alliances, R&D partnerships and commercial collaborations. In this edition, we highlight industry pacts that were sealed in May and June 2017.
MDxHealth has released results from a prospective study demonstrating biomarkers from its Confirm MDx prostate cancer test identifies men at increased risk of prostate cancer recurrence. The test could help urologists monitor therapy response to improve the personalized treatment of castration resistant prostate cancer (CRPC).
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Therapeutic Drug Monitoring
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
- Therapeutic Areas
- OncoGenome Sciences
- OncoMethylome Sciences SA
- Western Europe
- Parent & Subsidiaries
- MDxHealth SA
- Senior Management
Michael K McGarrity, CEO
Jean-Marc Roelandt, CFO
Joseph Sollee, EVP, Corp. Dev. & Gen. Counsel
Michael K Brawer, MD, CMO
- Contact Info
Phone: (32) 4 364 20 70
CAP Business Center
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.